Off-label Uses of Topical Pimecrolimus
- 3 May 2019
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 23 (4) , 442-448
Abstract
Pimecrolimus is a topical calcineurin inhibitor currently approved for second-line use in the management of mild-to-moderate atopic dermatitis in patients age 2 years and older. Given the safety profile and nonsteroidal mechanism of pimecrolimus, there has been significant interest in its use in the treatment of a variety of dermatological conditions. This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. Convincing evidence exists supporting pimecrolimus’ efficacy in oral lichen planus and seborrheic dermatitis. For other conditions studied to date, pimecrolimus may prove to be a useful treatment alternative when conventional agents fail. Adverse events seen with its off-label use were typically application site reactions, the most common being a transient burning sensation. In summary, pimecrolimus appears to be an effective agent in the treatment of multiple dermatological conditions and may be worth considering as a pharmacologic alternative in several conditions when first-line treatment fails, or for areas that are more susceptible to the adverse effects of topical corticosteroids.Keywords
This publication has 50 references indexed in Scilit:
- Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double‐blind controlled studyJournal of the European Academy of Dermatology and Venereology, 2013
- Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug useAdvances in Dermatology and Allergology, 2013
- A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosusJournal of the American Academy of Dermatology, 2011
- Oral lichen planus: An update on pathogenesis and treatmentJournal of Oral and Maxillofacial Pathology, 2011
- Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double‐blind controlled trialInternational Journal of Rheumatic Diseases, 2010
- Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot studyClinical and Experimental Dermatology, 2009
- A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitisJournal of the American Academy of Dermatology, 2008
- Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitisJournal of the American Academy of Dermatology, 2007
- Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationJournal of the American Academy of Dermatology, 2005
- Topical pimecrolimus in the treatment of human allergic contact dermatitisAnnals of Allergy, Asthma & Immunology, 2003